2021-12-20

The 2nd Symposium of Global Health Products and Commercialization organized by the Epoch Financial Institute for Zhejiang Entrepreneurs was held in Hangzhou on April 27, 2019. The topic this year was “seeking the most promising star businesses in China”. Rejuven Dermaceutical was invited to present as a representative of the pre-selected emerging star businesses. In the presentation, Rejuven presented its latest project progress. Its lead product RJV001 was completing its final phase of GLP tox studies. RJV001 is currently being prepared for US IND submission as a first-in-class drug to remodel subcutaneous adipose tissues.

2021-12-20

Rejuven Dermaceutical held pre-IND meeting with FDA of the US on January 14, 2019. Rejuven’s RJV001 as a new BLA will seek IND approval, and its development process including CMC, non clinical and cl...

2021-12-20

Rejuven Dermaceutical was invited to present its drug development business in the Biotech Showcase during the JP Morgan Healthcare Investment meeting in San Francisco on January 7-9, 2019. Over 3600 i...

2021-12-20

Rejuven won the 3rd place in 2018 SATOL (China) Roadshow The Second SATOL (China) Global Conference on Life Sciences and Technology was held in Hangzhou on December 8, attracting more than 30 academy ...

2021-12-20

In November 2018, Rejuven Dermaceutical was awarded the selective honor of “Enterprise of Hangzhou Science & Technology Startup Incubation Project in 2018”.

2021-12-20

On September 16, 2018 Rejuven Dermaceutical was invited to present in the Second Chinese Medical Esthetics Investment Summit held by Chinese Association of Plastics and Aesthetics in Shanghai. Rejuven reported its latest R & D update and financial prospect to the attending medical professionals, government agencies, pharmaceutical enterprises, venture capital firms.